Fritextsökning
Artiklar per år
Innehållstyper
-
Fewer visitors but satisfied exhibitors
Biotech Forum Scanlab attracted fewer visitors than in 2008. Exhibition manager Bo Rasmussen is content, claiming that the exhibitors are very satisfied.
-
"An open mind is the key to successful meetings"
Meeting in person is irreplaceble when it comes to finding a new partner. Johan Ohlsson at Venture Valuation is happy with his meetings at Biotech Forum so far and encourages Scandinavian companies to put themselves in the spotlight.
-
Mingling types - who to aim for and who to avoid:
Read about different mingling types - who are you?
-
How to be a perfect mingler
Linkedin, Facebook, MSN and Gmail are all perfect tools for the urban businessman or woman to keep track of and stay up-to-date with contacts. "But in the end, networking is about meeting and talking to people face-to-face," says mingling expert Mia Forsgren.
-
Density meters with six-digit precision
The new instruments from Krüss Optronic offer high sensitivity for density measurements.
-
Next generation sequencer in an accessible format
The GS Junior System is a new benchtop-sized next generation sequencing platform.
-
Your partnering tool - step by step
Profile, agenda and requests. Those are the basic steps to follow to use the partnering tool for Biotech Forum. Follow our guide to successful partnering!
-
Ozzy Osbournes DNA under lupp
Ett amerikanskt företag ska granska Ozzy Osbournes DNA för att ta reda på hur han kan ha överlevt 40 år av drog- och alkoholmissbruk.
-
Early stage research and low turnaround dominates
Nordic science parks are full of advanced research performed by small companies but little research is done in later stages. Only a couple of the best performers have companies in phase III, according to Biotech Scandinavia's survey.
-
Ideon - Sweden's oldest science park
Old is not synonymous with boring. Swedens oldest science park Ideon still manages to attract young companies with big ideas. The recipe for success? To continue to invest in further development.
-
Novo och Astra ligger bra till i internationell kraftmätning
Patentutgångar kommer under de närmaste åren att drabba flera stora läkemedelsbolag, men Astrazeneca och Novo Nordisk hör till de som skymtar ljusglimtar enligt en analys.
-
EU har siktet på Lundbeck
EU-kommissionen kommer att granska om den danska läkemedelsjätten har brutit mot EUs regler för konkurrens. Granskningen gäller hur Lundbeck har agerat kring generika av bolagets preparat citalopram.
BREAKING